The Role of Inhaled Insulin in the Management of Type 2 Diabetes

Nuffer, Wesley and Trujillo, Jennifer (2016) The Role of Inhaled Insulin in the Management of Type 2 Diabetes. Pharmacology & Pharmacy, 07 (04). pp. 162-169. ISSN 2157-9423

[thumbnail of PP_2016042111371278.pdf] Text
PP_2016042111371278.pdf - Published Version

Download (486kB)

Abstract

Type 2 diabetes continues to place a major burden on the health care system of the United States and worldwide. Type 2 diabetes involves two major defects: decreased insulin production from the pancreas and increased insulin resistance. Many patients with type 2 diabetes have decreased insulin production which requires exogenous insulin therapy in order to manage their disease. Despite this need, there is often a reluctance to initiate insulin therapy from both providers and patients. One reason for this reluctance may be a fear of needles or of administering injections. Delivering insulin through the lungs has been studied for decades, with the first inhaled insulin product coming to market in 2006. This product’s launch was considered unsuccessful, and the product was discontinued by the manufacturer the following year. A new inhaled insulin, Technosphere? insulin, was approved for use in type 1 and type 2 diabetes in 2014. This product was shown superior to placebo and non-inferior to a premixed bi-phasic subcutaneous insulin in patients with type 2 diabetes, and may offer an alternative to patients who are averse to giving subcutaneous injections.

Item Type: Article
Subjects: Research Asian Plos > Chemical Science
Depositing User: Unnamed user with email support@research.asianplos.com
Date Deposited: 04 Mar 2023 12:43
Last Modified: 19 Oct 2024 05:41
URI: http://abstract.stmdigitallibrary.com/id/eprint/216

Actions (login required)

View Item
View Item